Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.79 USD | 0.00% | -40.89% | -30.33% |
May. 15 | Top Midday Decliners | MT |
May. 15 | Bolt Biotherapeutics Stops Development of Trastuzumab Imbotolimod, Cuts Workforce by 50% | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.33% | 30.12M | |
+7.58% | 115B | |
+12.72% | 107B | |
-13.44% | 22.31B | |
-3.99% | 21.6B | |
-6.38% | 18.23B | |
-39.93% | 17.62B | |
+6.92% | 14.26B | |
+32.75% | 12.37B | |
-28.18% | 8.28B |
- Stock Market
- Equities
- BOLT Stock
- News Bolt Biotherapeutics, Inc.
- Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating